Publications by authors named "Howard Streicher"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

603

Total Likes

450

Extended Reach

3,992,965

Social Features

198
P
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers.
Jibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, Sarah J Shin, Naoko Takebe, Howard Streicher

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.
Joseph M Tuscano, Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Howard Streicher

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma.
Ahmad A Tarhini, Alyssa Obermayer, Sandra J Lee, William A LaFramboise, F Stephen Hodi, Howard Streicher

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort.
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z Win, Howard Streicher

Cancer Commun (Lond)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar, Howard Streicher

J Clin Endocrinol Metab· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Athalia R Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha, Howard Streicher

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors.
Megan Othus, Sandip P Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher

J Natl Cancer Inst· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar, Howard Streicher

J Clin Endocrinol Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer.
Vladimir Roudko, Diane Marie Del Valle, Emir Radkevich, Geoffrey Kelly, Xie Hui, Howard Streicher

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.
Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, Robert Edwards, Jennifer M Scalici, Howard Streicher

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves, Howard Streicher

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, David E Gerber, Tawee Tanvetyanon, Howard Streicher

Ther Adv Med Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Andrea B Apolo, Daniel M Girardi, Scot A Niglio, Rosa Nadal, Andre R Kydd, Howard Streicher

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh, Howard Streicher

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Nathan D Seligson, James L Chen, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell, Howard Streicher

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
Sandip P Patel, Megan Othus, Young Kwang Chae, Tridu Huynh, Benjamin Tan, Howard Streicher

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Howard Streicher

Nat Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.
Megan Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher

J Natl Cancer Inst· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Lakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, Shelly Lensing, Jeannette Lee, Howard Streicher

Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Howard Streicher

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Joanna Baginska, Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Howard Streicher

Cancer Immunol Immunother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Jacqueline S Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin K Tomlinson, Howard Streicher

Blood· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Livius Penter, Yang Liu, Jacquelyn O Wolff, Lin Yang, Len Taing, Howard Streicher

Blood· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Howard Z Streicher

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis